The NLRP3 Inflammasome Pathway: A Review of Mechanisms and Inhibitors for the Treatment of Inflammatory Diseases.
Blevins HM, Xu Y, Biby S, Zhang S. · 2022
Read The NLRP3 Inflammasome Pathway: A Review of Mechanisms and Inhibitors for the Treatment of Inflammatory Diseases. by Blevins HM, Xu Y, Biby S, Zhang S. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9226403.txt.
Introduction
Blevins and co-authors review the NLRP3 inflammasome pathway and drugs that block it for inflammatory diseases. NLRP3 is a protein complex that governs innate immunity and inflammatory signaling. When triggered, it activates caspase-1, which releases IL-1 beta and IL-18. Faulty activation drives several chronic inflammatory diseases.
Small molecules and biologics aimed at this pathway have shown good results in many disease models. Blocking it can calm chronic inflammation at its source. The review covers recent progress in how the complex works and where it acts in disease. It then surveys therapies found to target the pathway. Challenges for drug makers are discussed as well. Readers get a broad guide to a heavily studied drug target.
Catalog record
| CREATOR | Blevins HM, Xu Y, Biby S, Zhang S. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 156 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |